PharVision Advisers’s DaVita DVA Stock Holding History

PharVision Advisers’s Portfolio DVA Stock Details DVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,744	Closed	-$425K	–	265
2025 Q4	$425K	Buy	3,744 +2,187	+140%	+$266K	0.22%	96
2025 Q3	$207K	Buy	+1,557	New	+$214K	0.12%	488

Other funds holding DVA

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's DVA Position: Q1 2026 in Review

PharVision Advisers sold out of DaVita (DVA) in Q1 2026, closing a stake of 3,744 shares — an estimated $425K sold.

PharVision Advisers first reported a position in DVA in Q3 2025 and held it in 2 quarters. The position peaked at $425K in Q4 2025. 583 funds tracked by Wall St. Rank hold DVA as of Q1 2026.

PharVision Advisers reported no remaining DaVita position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,744 DaVita shares in Q1 2026, an estimated $425K.
PharVision Advisers first reported a position in DaVita in Q3 2025 and held it in 2 quarters.
PharVision Advisers's DaVita position peaked at $425K in Q4 2025.
583 funds tracked by Wall St. Rank held DaVita as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.